GLP-1 Market to Surge from $70B to $202B by 2033 on 12.8% CAGR
The global GLP-1 receptor agonist market reached $70.08 billion in 2025 and is forecast to grow at a 12.78% CAGR to $201.79 billion by 2033, driven by rising obesity and diabetes prevalence and robust R&D pipelines. Novo Nordisk’s leading GLP-1 products, including Ozempic and Wegovy, position it to capture a significant share of this expanding market.
1. Market Size & Forecast
The global GLP-1 receptor agonist market reached $70.08 billion in 2025 and is projected to expand at a 12.78% compound annual growth rate to $201.79 billion by 2033, highlighting significant long-term growth potential.
2. Growth Drivers and Company Positioning
Rising obesity and diabetes prevalence, robust research and development pipelines, and high drug efficacy underpin this expansion, positioning Novo Nordisk’s flagship GLP-1 products—Ozempic and Wegovy—to capture substantial market share.